A 16-residue synthetic peptide corresponding to the N-terminal sequence of p6o rc was used as the acyl acceptor in an assay for myristoyl-CoA :glycylpeptide N-myristoyltransferase in rat tissues. An additional C-terminal tyrosine amide was added to this peptide to facilitate radioiodination and enhance detectability. Reverse-phase h.p.l.c. enabled the simultaneous detection and quantification of the peptide substrate and its N-myristoylated product. N-Myristoyltransferase activity was highest in the brain with decreasing activities in lung, small intestine, kidney, heart, skeletal muscle and liver. Brain activity was distributed approximately equally between the 100000g pellet and supernatant fractions. The soluble enzyme exhibited a K0PP of 20 /tM for the src peptide and an optimum between pH 7.0 and 7.5. Maximum N-acylating activity was seen with myristoyl (C14:0)-CoA with lower activities found with the C10:0-CoA and C12 0-CoA homologues. No activity was obtained with palmitoyl (C18: 0)-CoA but this derivative inhibited N-myristoyltransferase activity > 500 at equimolar concentrations with myristoyl-CoA. With a decapeptide corresponding to the N-terminal sequence of the cyclic AMP-dependent protein kinase catalytic subunit as the acyl acceptor, the brain enzyme displayed a K0PP-of 117 /M and was about 14-fold less catalytically effective than with the p6Osrc acyl acceptor. Transferase activity was also seen with a 16-residue peptide corresponding to the Nterminal sequence of the HIV pI7gag structural protein. Inhibition studies with shorter src peptide analogues indicated an enzyme specificity for the p6o8rC acyl acceptor beyond 9 residues.
INTRODUCTION
The transforming product of the Rous sarcoma virus is a tyrosine kinase with an Mr of 60000 termed p60V8rc. Both it and its cellular homologue, p60-8rc, are localized to the inner surface of the plasma membrane [1] [2] [3] [4] [5] . The transforming activity of the viral enzyme appears to depend upon this membrane localization [1] [2] [3] [4] [5] [6] [7] . It has been shown that this membrane association requires the addition of myristic acid to the N-terminal glycine via an amide linkage [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Mutant viruses in which the v-src product contained N-terminal amino acid deletions [7, 8] or in which the N-terminal glycine was replaced with alanine or glutamic acid [12] all failed to incorporate myristic acid. These mutant proteins were still functional kinases in vitro and in vivo, but instead of being localized to the membrane, they were found predominantly in the cytoplasm. Most significantly, these mutant kinases no longer transformed cells. These as well as other studies indicate that N-myristoylation is an essential step in p60v-srcdependent transformation.
It appears that the sequence information within the first 14 N-terminal amino acids of the c-src or v-src kinases is sufficient for their N-myristoylation [7, 8] . It has been shown that when a heterologous gene is constructed by fusing the N-terminal 14 amino acid sequence of p60*rc to that of a nonmyristoylated cytoplasmic protein, the resulting hybrid gene product becomes N-myristoylated and membrane-associated [11] . In addition, since N-myristoylation may occur by a co-translational process [14] , it is possible that nascent polypeptide chains are the actual substrates of the Nmyristoyltransferase(s) [14] . In this paper we have used a 16-amino-acid synthetic peptide homologous to the Nterminal amino acid sequence of p60*rc as the acyl acceptor in an assay for the N-myristoyltransferase(s) responsible for p608rc N-myristoylation in mammalian tissues. We have used this assay to establish a wide distribution of N-myristoyltransferase activities in rat tissues. In addition, the preliminary characterization of the N-myristoyltransferase activity from rat brain allowed a comparison with a recently reported yeast enzyme which was assayed using a synthetic octapeptide corresponding to the N-terminal amino acid sequence of cyclic AMP-dependent protein kinase catalytic subunit [17] [18] [19] . N-Myristoylation is an essential step in p60v-rc transforming activity. In addition, it may be important for the transformation activities of a variety of viral myristoylated gag-onc fusion proteins [20] [21] [22] . Consequently, Nmyristoyltransferase(s) could represent an important new target for the inhibition or reversal of these Nmyristoylation-dependent transformations. Vol. 250 minced with scissors and homogenized in 20 mM-Tris/ HCl, pH 7.4, containing 1 mM-EDTA, 1 mM-dithiothreitol and 8 ,tg of pepstatin, 20 ,sg of leupeptin and 0.5 mg of aprotinin/ml (1 g of tissue/6 ml) for 15 s at 5000 maximum power with a Polytron homogenizer (model PCU) equipped with a PT-10-ST probe (Brinkman Instruments, Westbury, NY, U.S.A.) at 0-4 'C. The homogenates were centrifuged at 100000 g for 60 min in an ultracentrifuge (model L5-50, Beckman Instruments). The high speed supernatant fractions were removed and the pellets washed twice by resuspension in the original volume of homogenization buffer using a Dounce homogenizer. The pellets were then recentrifuged and finally resuspended as described above. Samples of the original homogenates and the washed high speed pellet and supernatant fractions from brain were stored at -70 'C and thawed immediately prior to use. Synthetic peptides Synthesis and purification of peptides was performed by Peptide Technologies Inc. (Washington, DC, U.S.A.). Peptide amides were synthesized by standard solid phase methodologies on a p-methylbenzhydrylamine resin [23] . The synthetic N-myristoylated peptides were prepared by acylating the free terminal amino group with myristate by carbodi-imide activation before the resin was deblocked and cleaved. The crude peptides were purified by counter-current preparative reversed phase h.p.l.c. or ion exchange chromatography. The purity and identity of the peptides were established by reversed phase h.p.l.c., t.l.c. and amino acid analysis. lodination and purification of radiolabelled peptides An additional noncoded C-terminal tyrosine was included in some peptides to facilitate radioiodination by the method of Hunter & Greenwood [24] . A peptide (2 nmol in 10 4t1 of deionized water) and 10 ,u of 0.33 Mpotassium phosphate buffer, pH 7.0, were added to the original vial containing 1 mCi of carrier free Na'25I (New England Nuclear). The iodination was initiated by the addition of 10 ,ul of 0.5 mM-chloramine T (2.5 nmol) and allowed to proceed at room temperature for 1 min. The reaction was terminated by the addition of 40,1 of 0.31 mM-sodium metabisulphite (12.4 nmol), allowed to stand for 3 min prior to the addition of 100 1ul of 1 mMNal. The iodinated peptides were purified using a C18 Sep-Pak cartridge (Waters, Bedford, MA, U.S.A.). The reaction mix was applied to the cartridge, followed by a 0.5 ml 0.1 % trifluoroacetic acid wash of the reaction vessel. The separation of labelled peptide from contaminating 1251 was achieved by eluting the Sep-Pak with increasing concentrations of acetonitrile in a water/ 0.1 % trifluoroacetic acid/acetonitrile mix (3 ml with 0 % acetonitrile, 2 ml 10 %, 4 x 0.5 ml 25 %, 3 x I ml 50 % and 3 x 1 ml 75 %). Eluted fractions were collected and the radioactivity determined by gamma counting. The p60src and cAMPdPK N-glycylpeptides were eluted with 25 % acetonitrile, the p608rc and cAMPdPK N-myristoylglycylpeptides and the gag N-glycylpeptide were eluted with 50 % acetonitrile, and the gag N-myristoylglycylpeptide was eluted with 75 % acetonitrile. Appropriate fractions were combined, dried with a stream of N2 at 50 'C, dissolved in 100 % dimethyl sulphoxide and stored at -20°C.
EXPERIMENTAL
Radioiodination of the src N-glycylpeptide produced one major (80-90 %) and one minor radioactive peak which eluted between 5 and 6 min on reversed phase h.p.l.c. (see Fig. 1 The stoichiometry for rat brain N-myristoylation was determined by incubating non-radioactive or radio- lysine, thus confirming the N-myristoylation of the Nterminal glycine. N-Myristoyltransferase activity was identified in rat brain using the p608rC N-glycyl[125I]peptide acyl acceptor in the assay described in the Experimental section. Using this assay, the enzyme activity found in the crude brain homogenate was distributed approximately equally between the 100000 g supernatant fraction (55 %) and the twice-washed crude membrane pellet (45 %). All subsequent characterizations described were carried out on the enzyme activity found in the soluble fraction.
The N-myristoyltransferase activity in rat brain was heat-labile with maximum activity dependent upon the presence of myristoyl-CoA as the acyl donor (Tables 1  and 2 reaction. The enzyme displayed a pH optimum between pH 7.0 and 7.5 (Fig. 3) . N-Myristoyltransferase acyl-CoA specificity
The relative N-myristoyltransferase acyl-CoA donor specificity was examined with the p60trc N-glycyl[125l]-peptide acceptor using various acyl-CoA substrates in place of myristoyl-CoA (Table 2 ). Retention times of the single product peaks were dependent upon the acyl chain lengths of the various acyl peptides. The highest Nacyltransferase activity was seen with myristoyl-CoA as cosubstrate and was expressed as 100 % (Table 2) . Lower acyltransferase activities also were seen for n-decanoyl (Fig. 2) . A comparison of Vmax /Km values (i.e. 5.9 x 105 and 0.42x lO5 pmol min-M-l, respectively), which should be proportional to pseudo-second-order rate constants, suggested a 14-fold greater catalytic efficiency of the enzyme for the p6Osrc acyl acceptor compared with the cAMPdPK acyl acceptor. The stability of the p608cr and cAMPdPK N-myristoylglycyl[125I]peptides under the conditions of the kinetic experiments was confirmed, substantiating that the differences in transferase activities were not due to a differential stability of the enzymic product. The brain enzyme exhibited negligible activity toward a pI71a9 peptide acceptor at 100 uM but low activity was apparent using 750 ,#M-acyl peptide acceptor.
These results demonstrate a rather marked preference for the p6o8rC acyl acceptor compared with these two other peptide acceptors. It remains to be determined if this catalytic preference reflects the activity of multiple enzymes or results from the catalytic preference of a single enzyme for different peptides under these conditions. However, the results do suggest an N-myristoyltransferase recognition of these synthetic peptides that extends beyond the common N-terminal glycine residue.
Peptide inhibitors of N-myristoyltransferase
Various sized synthetic N-glycylpeptides and their Nmyristoylglycylpeptide counterparts corresponding to the N-terminal amino acid sequence of p608rc were examined as inhibitors of N-myristoyltransferase (Table  3) . Non-radioactive N-myristoylglycylpeptides of 3, 5, 7, 9 or 15 amino acid residues at a 50-fold molar excess over the src N-glycyl[1251]peptide acyl acceptor showed an increasing inhibition of N-myristoyltransferase with increasing peptide length. The data in Table 3 indicate that an N-acyl peptide of more than three residues is required for inhibition; however the magnitude of this size-dependent inhibition is uncertain due to the increasing insolubility of the shorter peptides under our assay conditions. In contrast with the marked inhibition by Nmyristoylglycyl peptides, comparable inhibition by a series of nonmyristoylated peptides was only evident for the p6o.rC homologues with more than seven residues. Both the 16-residue p608.c and pl7gag peptides inhibited > 85 %. However, a 10-residue cAMPdPK peptide inhibited about 30 % compared with a similar sized 9-residue src peptide that inhibited by about 60 %. 
DISCUSSION
No viral genes are known to encode for enzymes catalysing N-myristoylation. Consequently, the transferase(s) necessary for p60V 8rc N-myristoylation must be of cellular origin and they must play a role in normal cell function. Besides the cellular p60c-8rc kinase encoded by the src proto-oncogene which is also N-myristoylated [16] , at least two other important cellular enzymes have been shown to be N-myristoylated: the catalytic subunit of cAMPdPK [27] and the calmodulin binding phosphatase, calcineurin B [28] . Both of these latter proteins can also be membrane associated and are thought to be regulators of normal cell growth and differentiation [29] [30] [31] .
The enzyme assay described in this study was designed to identify the N-myristoyl transferase(s) responsible for p608rc N-myristoylation in mammalian tissues. The peptide acyl acceptor we used included the N-terminal 1-14 p60 8c amino acid sequence thought to be necessary for N-myristoylation in vivo [12] . Using this p608rc Nglycyl[125I]peptide as the acyl acceptor, we have identified N-myristoyl transferase activity in every rat tissue examined. It may be significant that brain, which has the highest specific activity of any tissue examined, is also known to be a rich source of p60"8rc in developing neural tissues [32, 33] . The lower levels of transferase in other rat tissues correspond to recent evidence indicating that normal human liver, kidney, and skeletal muscle contain 15-30-fold lower levels of p60c-8rc compared with normal human brain [34] . Brain is also known to be a rich source of two other N-myristoylated proteins, calcineurin B and cAMPdPK [35, 36] . The level of bovine calcineurin B is at least 10-fold higher in brain compared with most other tissues [35] . The rat tissue distribution of cAMPdPK also is similar to that of N-myristoyltransferase except for the presence of kinase activity in heart at levels nearly equal to that found in brain and lung [36] . We examined the possibility that heart contains N-myristoyltransferase activity with specificity for cAMPdPK by utilizing a decapeptide corresponding to the N-terminal sequence of cAMPdPK catalytic subunit as the acyl acceptor. The Nmyristoyltransferase tissue distribution using the cAMPdPK acceptor was identical with that found with the p608rc acceptor, suggesting that a single enzyme is responsible for the N-myristoylation of both peptides.
A similar N-myristoyltransferase activity has been recently described in yeast and murine tissue culture cells by the transfer of radiolabelled myristoyl-CoA to a non-radioactive octapeptide homologous to the N-terminal sequence of cAMPdPK catalytic subunit [17] [18] [19] . The rat brain enzyme described in our studies exhibits a number of properties similar to that previously described yeast enzyme. Considering the low natural abundance of short chain saturated fatty acids (< C14) compared with myristate in rat tissues [37] and in yeast [38] it is probable that the enzymes described in both studies function as strict Nmyristoyltransferases in vivo. A similar specificity of p6O8rC N-acylation for myristic acid has been determined by metabolic labelling [7, 15] . In addition, whereas the C16:0 acyl-CoA exhibited negligible activity for either the rat or the yeast enzymes, it did inhibit N-myristoyltransferase activity in both. However, in contrast with the yeast enzyme in which the < C14:0 acyl-CoA derivatives were better inhibitors than the C16:0 acylCoA, for the rat enzyme the C16:0 acyl-CoA was about twice as effective an inhibitor as was the C1o:0 or C12:0 acyl-CoAs. (3) Both the rat and the yeast enzymes catalyse the N-myristoylation of N-glycylpeptides homologous to the N-terminal sequences of p6O8rC, pl7gag and cAMPdPK catalytic subunit. Although there is general agreement in the relative kinetic constants for the two enzymes, a strict comparison is not possible because of the use of slightly different N-glycylpeptide acyl acceptors and different assay conditions. Keeping this in mind, we found about a 3-fold greater activity with the p608rc compared with the cAMPdPK N-glycylpeptides in rat brain. This compares to a greater than 2-fold higher activity exhibited by the yeast enzyme for the cAMPdPK acyl acceptor compared with the p608rC acyl acceptor but apparently the reverse specificity in a murine cell line [18] .
N-Myristoyltransferase(s) display an absolute requirement for N-terminal glycine [9] [10] [11] [12] [13] [14] [15] [16] . Besides this Nterminal glycine there are no other sequence homologies among the five known N-myristoylated proteins except possibly a frequently occurring hydroxyamino acid in position five. Thus, N-myristoylation may be catalysed either by a family of transferases each with a unique sequence specificity for a different protein acyl acceptor or by a single enzyme with a broad peptide sequence recognition specificity. It is also possible that there is no consensus N-myristoylation sequence beyond N-terminal glycine and that acylation is dependent upon an as yet unrecognized conformation-dependent recognition site [10] . An analogous conformation-dependent specificity within the first 40 N-terminal residues has been postulated for N-acetylation [39] .
Although our analysis does not allow a final assessment of these possibilities, the different catalytic rates observed with the p6osrc, 8 79ga" and cAMPdPK acyl acceptors and the results of the inhibition studies indicate that the brain enzyme(s) exhibit amino acid sequence requirements beyond the N-terminal glycine. More specific information on acyl acceptor amino acid sequence preference is suggested by the inhibition of N-myristoyltransferase by synthetic N-glycylpeptides corresponding to the Nterminal sequence of src. Assuming that these peptides inhibit by functioning as alternative competitive substrates, then the significant inhibition which was evident only with peptides with more than five residues indicates an enzyme recognition of the peptide acyl acceptor beyond position 5. A similar dependence of the yeast enzyme on the presence of a lysine at position 7 is consistent with this conclusion [18] . In addition, the increasing inhibition by 7-, 9-, and 16-residue peptides may indicate a p608rc N-myristoyltransferase preference either for specific amino acid residues beyond position 9 or for a peptide substrate of larger than nine residues as well.
N-Myristoylation is thought to be an important cellular event. The fact that such a rare fatty acid is incorporated with such strict specificity into cellular enzymes with broad regulatory effects suggests that this process may have a central role in the control of normal cellular growth and differentiation. In addition, the association of N-myristoylation with a number of transforming tyrosine kinases as well as its obligatory role in p60v8rc transformations suggest that it may be a potential new target for blocking or reversing certain types of malignancies.
